12 May 2022>: Clinical Research
Retrospective Study from a Single Center to Evaluate the Association Between Sex and Serum Uric Acid Levels in 950 Patients with Atrial Fibrillation
Xia Zhong 1ABCE , Huachen Jiao 2BDFG* , Dongsheng Zhao 1BCD , Jing Teng 1ADFDOI: 10.12659/MSM.935273
Med Sci Monit 2022; 28:e935273
Table 1 Baseline and clinical characteristics of control group and atrial fibrillation group.
Variable | Control group (n=963) | AF group (n=950) | P value |
---|---|---|---|
Age, years | 67.92±11.66 | 68.61±10.34 | 0.171 |
Male, n (%) | 470 (48.8) | 479 (50.4) | 0.480 |
Hypertension, n (%) | 324 (33.6) | 638 (67.2) | * |
CHD, n (%) | 241 (25.0) | 840 (88.4) | * |
Diabetes, n (%) | 158 (16.4) | 280 (29.5) | * |
Serum creatinine, μmoI/L | 64.77±26.54 | 78.46±51.47 | * |
AST, U/L | 20.76±10.81 | 25.30±45.62 | 0.003* |
ALT, U/L | 20.27±13.64 | 22.30±27.37 | 0.041* |
APOA1, g/L | 1.23±0.25 | 1.13±0.26 | * |
APOB, g/L | 0.99±0.24 | 0.80±0.38 | * |
ALB, g/L | 40.11±4.12 | 38.05±4.64 | * |
PAB, mg/L | 222.57±55.02 | 195.61±59.43 | * |
Lp (a), mg/dL | 22.56±24.34 | 23.55±26.88 | 0.399 |
TG, mmol/L | 1.38±1.24 | 1.24±0.88 | 0.004* |
TC, mmol/L | 5.02±1.10 | 4.19±1.10 | * |
LDL-C, mmol/L | 2.96±0.86 | 2.50±0.90 | * |
HDL-C, mmol/L | 1.21±0.25 | 1.07±0.30 | * |
SUA, mg/dL | 5.21±1.50 | 5.71±1.91 | * |
Male, mg/dL | 5.80±1.46 | 6.07±1.89 | * |
Female, mg/dL | 4.64±1.30 | 5.34±1.86 | * |
Hyperuricemia, n (%) | 180 (18.69) | 301 (31.68) | * |
Male | 96 (9.97) | 141 (14.84) | * |
Female | 84 (8.72) | 160 (16.84) | * |
Data are presented as mean±SD or n(%). AF – atrial fibrillation; CHD – coronary heart disease; AST – aspartate aminotransferase; ALT – alanine aminotransferase; APOA1 – serum apolipoprotein A1; APOB – serum apolipoprotein B; ALB – albumin; PAB – prealbumin; Lp (a) – lipoprotein (a); TG – triglyceride; TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; SUA – serum uric acid. * Statistically significant value ( |